Literature DB >> 12696005

Antibody-dependent enhancement, a possible mechanism in augmented pulmonary disease of respiratory syncytial virus in the Bonnet monkey model.

Esther M Ponnuraj1, Jennifer Springer, Anthony R Hayward, Harry Wilson, Eric A F Simoes.   

Abstract

Bonnet monkeys develop an enhanced disease after immunization with the formalin-inactivated (FI) respiratory syncytial virus (RSV) vaccine that is characterized by increased viral replication in perivascular sites of the lung. These sites contain many mononuclear cells, which are known to be permissive for RSV replication. To test the hypothesis that FI-RSV vaccine stimulates the production of enhancing antibodies that serve to increase the replication of RSV in macrophages, in vitro studies were done. Antibody-dependent enhancement was observed in animals immunized with FI-RSV but not in control animals with primary and tertiary infections or those immunized with FI-Vero cell culture. In the presence of serum samples from animals immunized with FI-RSV, an increased number of U937 cells was infected. The enhancement index correlated positively with the pathologic scores of the FI-RSV-vaccinated monkeys.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12696005     DOI: 10.1086/374604

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  24 in total

Review 1.  How innate immune mechanisms contribute to antibody-enhanced viral infections.

Authors:  Sukathida Ubol; Scott B Halstead
Journal:  Clin Vaccine Immunol       Date:  2010-09-28

2.  Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner.

Authors:  Erin Mehlhop; Camilo Ansarah-Sobrinho; Syd Johnson; Michael Engle; Daved H Fremont; Theodore C Pierson; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2007-12-13       Impact factor: 21.023

3.  Could vaccination with AIDSVAX immunogens have resulted in antibody-dependent enhancement of HIV infection in human subjects?

Authors:  Evgeny Shmelkov; Arthur Nadas; Timothy Cardozo
Journal:  Hum Vaccin Immunother       Date:  2014-11-21       Impact factor: 3.452

4.  Live Respiratory Syncytial Virus (RSV) Vaccine Candidate Containing Stabilized Temperature-Sensitivity Mutations Is Highly Attenuated in RSV-Seronegative Infants and Children.

Authors:  Ursula J Buchholz; Coleen K Cunningham; Petronella Muresan; Devasena Gnanashanmugam; Paul Sato; George K Siberry; Vivian Rexroad; Megan Valentine; Charlotte Perlowski; Elizabeth Schappell; Bhagvinji Thumar; Cindy Luongo; Emily Barr; Mariam Aziz; Ram Yogev; Stephen A Spector; Peter L Collins; Elizabeth J McFarland; Ruth A Karron
Journal:  J Infect Dis       Date:  2018-04-11       Impact factor: 5.226

Review 5.  A Structural and Mathematical Modeling Analysis of the Likelihood of Antibody-Dependent Enhancement in Influenza.

Authors:  Boopathy Ramakrishnan; Karthik Viswanathan; Kannan Tharakaraman; Vlado Dančík; Rahul Raman; Gregory J Babcock; Zachary Shriver; Ram Sasisekharan
Journal:  Trends Microbiol       Date:  2016-10-14       Impact factor: 17.079

6.  Respiratory syncytial virus vaccine: Is it coming?

Authors:  Valérie Sales; Elaine El Wang
Journal:  Paediatr Child Health       Date:  2003-12       Impact factor: 2.253

Review 7.  Dengue virus pathogenesis: an integrated view.

Authors:  Byron E E Martina; Penelope Koraka; Albert D M E Osterhaus
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

Review 8.  Beyond binding: antibody effector functions in infectious diseases.

Authors:  Lenette L Lu; Todd J Suscovich; Sarah M Fortune; Galit Alter
Journal:  Nat Rev Immunol       Date:  2017-10-24       Impact factor: 53.106

Review 9.  Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease.

Authors:  Patricio L Acosta; Mauricio T Caballero; Fernando P Polack
Journal:  Clin Vaccine Immunol       Date:  2015-12-16

10.  Intranasal administration of antibody-bound respiratory syncytial virus particles efficiently primes virus-specific immune responses in mice.

Authors:  Debby Kruijsen; Helga K Einarsdottir; Marcel A Schijf; Frank E Coenjaerts; Ellen C van der Schoot; Gestur Vidarsson; Grada M van Bleek
Journal:  J Virol       Date:  2013-05-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.